— Know what they know.
Not Investment Advice

ZVRA NASDAQ

Zevra Therapeutics, Inc.
1W: -3.9% 1M: -11.0% 3M: +2.9% YTD: +20.6% 1Y: -5.2% 3Y: +138.9% 5Y: +3.8%
$10.05
+0.53 (+5.51%)
 
Weekly Expected Move ±8.3%
$8 $9 $10 $11 $11
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 35 · $597.1M mcap · 54M float · 2.09% daily turnover · Short 64% of daily vol
Credit Risk of going bust: lower than 84% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Zevra Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $597.1M.
Distance to default 10.75 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $748K (short-term plus half of long-term), stock volatility 60.9%; Altman Z'' 4.62. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

WEAK EDGE
48.6 / 100
NoneWeakNarrowWide
Primary source: Network Effects  ·  ROIC: -1356.4%
Cost Advantage
54
Intangibles
51
Switching Cost
40
Network Effect
78
Scale
22
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. ZVRA shows a Weak competitive edge (48.6/100) — limited structural advantages that may face competitive pressure. The primary source of advantage is Network Effects. Negative ROIC of -1356.4% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$0
Low
$26
Avg Target
$26
High
Based on 11 analyst ratings (12 mo)
Analyst Recommendations
Strong Buy: 0Buy: 10Hold: 0Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$25.73
Analysts11
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-07-27 Guggenheim — $29 $24 -5 +152.0% $9.53
2026-07-27 BTIG Kambiz Yazdi Initiated $24 — +152.0% $9.53
2026-07-27 Canaccord Genuity Sumant Kulkarni $29 $20 -9 +110.0% $9.53
2026-06-10 Maxim Group Jason McCarthy $25 $35 +10 +156.1% $13.67
2026-06-10 Guggenheim Eddie Hickman $25 $29 +4 +112.3% $13.66
2026-06-09 Canaccord Genuity Sumant Kulkarni $24 $29 +5 +139.9% $12.09
2026-05-08 Guggenheim Eddie Hickman $23 $25 +2 +127.3% $11.00
2026-03-10 Guggenheim Eddie Hickman $22 $23 +1 +108.5% $11.03
2025-12-30 H.C. Wainwright Brandon Folkes $20 $26 +6 +194.8% $8.82
2025-11-06 Cantor Fitzgerald Kristen Kluska Initiated $24 — +158.5% $9.29
2025-11-06 Canaccord Genuity — $22 $24 +2 +168.2% $8.95
2025-03-13 Guggenheim — $21 $22 +1 +177.1% $7.94
2025-03-12 JMP Securities — $17 $18 +1 +127.3% $7.92
2025-02-04 Guggenheim Zevra Therapeutics to $ Initiated $21 — +158.3% $8.13
2024-09-24 Roth Capital Jonathan Aschoff Initiated $21 — +177.0% $7.58
2024-09-24 Maxim Group Jason McCarthy Initiated $25 — +229.8% $7.58
2024-09-23 JMP Securities Jason Butler Initiated $17 — +124.3% $7.58
2024-09-23 H.C. Wainwright Oren Livnat Initiated $20 — +152.5% $7.92
2024-09-18 Canaccord Genuity Sumant Kulkarni Initiated $22 — +192.2% $7.53

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

A-
Oct 27, 2026
DCF
1
ROE
5
ROA
5
D/E
4
P/E
3
P/B
2
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. ZVRA receives an overall rating of A-. Strongest factors: ROE (5/5), ROA (5/5), D/E (4/5). Areas of concern: DCF (1/5), P/B (2/5).
Rating Change History
DateFromTo
2026-10-12 B+ A-
2026-08-12 A- B+
2026-08-10 B A-
2026-08-06 A- B
2026-05-11 A A-
2026-05-07 C- A
2026-05-06 B+ C-
2026-04-24 B B+
2026-04-01 B+ B
2026-01-16 C+ B+

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 76 Grade A
Profitability
98
Balance Sheet
95
Earnings Quality
47
Growth
79
Value
58
Momentum
78
Safety
100
Cash Flow
68
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. ZVRA scores highest in Safety (100/100) and lowest in Earnings Quality (47/100). An overall grade of A places ZVRA among the highest-quality companies in its peer group.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
6.50
Safe Zone
Piotroski F-Score
6/9
✓ ✓ ✓ ✗ ✓ ✗ ✗ ✓ ✓
Beneish M-Score
-1.71
Possible Manipulator
Ohlson O-Score
-10.17
Bankruptcy prob: 0.0%
Low Risk
Credit Rating
AA+
Score: 94.7/100
Trend: Improving
Earnings Quality
50/100
OCF/NI: 0.57x
Accruals: 8.9%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. ZVRA scores 6.50, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. ZVRA scores 6/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. ZVRA's score of -1.71 exceeds the −1.78 red flag threshold — this does not confirm manipulation but indicates the earnings profile resembles past manipulators statistically. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. ZVRA's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. ZVRA receives an estimated rating of AA+ (score: 94.7/100), with a improving trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). ZVRA's score of 50/100 is moderate — some divergence between reported earnings and underlying cash flows.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
10.49x
PEG
0.01x
P/S
4.40x
P/B
2.74x
P/FCF
26.96x
P/OCF
26.34x
EV/EBITDA
9.03x
EV/Revenue
4.85x
EV/EBIT
9.21x
EV/FCF
20.21x
Earnings Yield
6.62%
FCF Yield
3.71%
Shareholder Yield
0.00%
Graham Number
$8.71
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 10.5x earnings, ZVRA trades at a reasonable valuation. An earnings yield of 6.6% exceeds typical risk-free rates, suggesting equities are being compensated for risk. Graham's intrinsic value formula yields $8.71 per share, 15% below the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.841
NI / EBT
×
Interest Burden
0.968
EBT / EBIT
×
EBIT Margin
0.526
EBIT / Rev
×
Asset Turnover
0.487
Rev / Assets
×
Equity Multiplier
1.669
Assets / Equity
=
ROE
34.8%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. ZVRA's ROE of 34.8% is driven by a balanced combination of operating margin, asset efficiency, and leverage.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
15.00%
Fair P/E
38.50x
Intrinsic Value
$36.57
Price/Value
0.39x
Margin of Safety
60.79%
Premium
-60.79%
Assessment
Neutral
Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with ZVRA's realized 15.0% 3-year EPS CAGR, capped at 15% — demonstrated performance rather than forecasts, held to a rate companies have historically sustained. ZVRA trades at a -61% premium to its adjusted intrinsic value of $36.57, suggesting the market is pricing in future growth beyond what historical earnings support. The adjusted fair P/E of 38.5x compares to the current market P/E of 10.5x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$10.06
Median 1Y
$6.64
5th Pctile
$1.80
95th Pctile
$24.61
Ann. Volatility
84.4%
25th–75th percentile 5th–95th percentile Median path Historical

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
R. LaDuane Clifton
, MBA, CPA Former Chief Financial Officer and Treasurer
$477,307 $1,260,373 $3,821,924
Neil F. McFarlane
President, Chief Executive Officer and Director
$729,167 $874,125 $3,782,042
Rahsaan W. Thompson
Chief Legal Officer, Secretary and Compliance Officer
$466,667 $272,680 $1,571,374

CEO Pay Ratio

3:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $3,782,042
Avg Employee Cost (SGA/emp): $1,272,393
Employees: 61

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
61
+3.4% YoY
Revenue / Employee
$1,745,410
Rev: $106,470,000
Profit / Employee
$1,364,410
NI: $83,229,000
SGA / Employee
$1,272,393
Avg labor cost proxy
R&D / Employee
$208,902
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
ROE -30.9% -28.2% -0.1% -26.4% -31.2% -41.1% -54.8% -37.5% -43.6% -60.3% -74.4% -1.2% -1.2% -2.1% -2.0% 3.5% 34.8% 85.7% 1.0% 34.8% 34.80%
ROA -14.4% -11.9% -0.1% -23.1% -27.4% -33.5% -45.5% -27.4% -27.2% -28.7% -34.7% -49.7% -51.4% -60.2% -56.8% 1.3% 15.3% 36.0% 55.1% 20.8% 20.85%
ROIC 3.0% 37.3% -4.0% -76.8% -88.7% -3.0% 4.3% 5.4% -1.2% -1.0% -1.1% -1.4% -1.7% -2.3% -1.4% 63.7% 15.9% -2.3% -40.8% -13.6% -13.56%
ROCE -6.5% -6.3% -0.0% -26.5% -32.2% -40.8% -58.7% -35.7% -32.5% -44.4% -38.4% -54.3% -50.5% -57.5% -45.8% 13.1% 25.4% 38.6% 59.5% 28.2% 28.17%
Gross Margin 1.0% 97.7% 99.8% 96.1% 95.1% 93.8% 96.1% 92.0% 95.0% 78.9% 4.7% 19.7% 37.7% 88.7% 93.4% 52.2% 94.0% 95.5% 93.7% 96.2% 96.16%
Operating Margin -1.1% -1.1% -46.9% -19.1% -2.3% -4.0% -4.0% -73.8% -5.3% -1.1% -6.0% -5.3% -7.4% -1.3% -26.3% -2.7% 15.9% 27.3% 24.4% 42.3% 42.30%
Net Margin -89.5% -1.0% -47.0% -18.5% -2.3% -3.9% -4.2% -30.4% -3.6% -1.1% -4.9% -4.5% -9.0% -3.0% -15.2% 2.9% -2.1% 35.6% 1.0% 22.1% 22.07%
EBITDA Margin -85.9% -1.0% -45.3% -18.9% -2.1% -3.8% -4.1% -28.0% -4.6% -1.1% -4.2% -3.6% -7.9% -1.4% 8.3% 3.1% 5.6% 43.9% 1.2% 33.2% 33.17%
FCF Margin 35.6% 36.1% 46.0% -1.2% -1.4% -1.8% -2.0% -1.4% -1.3% -1.2% -1.6% -2.3% -2.8% -3.0% -1.5% -75.0% -28.7% -2.3% 9.8% 24.0% 23.98%
OCF Margin 36.0% 36.4% 46.5% -1.1% -1.4% -1.8% -2.0% -1.4% -1.3% -1.2% -1.6% -2.3% -2.8% -3.0% -1.5% -74.5% -27.7% -1.5% 10.4% 24.5% 24.55%
ROE 3Y Avg snapshot only -54.03%
ROE 5Y Avg snapshot only -47.71%
ROA 3Y Avg snapshot only -7.57%
ROIC Economic snapshot only 15.18%
Cash ROA snapshot only 11.03%
NOPAT Margin snapshot only 24.14%
Pretax Margin snapshot only 50.92%
R&D / Revenue snapshot only 10.97%
SGA / Revenue snapshot only 54.85%
SBC / Revenue snapshot only 9.65%
Valuation
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
P/E Ratio -30.69 -35.99 -1411.12 -5.06 -6.11 -3.81 -3.58 -5.50 -4.76 -6.01 -5.42 -3.31 -3.91 -4.24 -4.40 187.68 15.06 6.16 4.52 15.10 10.489
P/S Ratio 11.56 10.75 8.47 15.66 20.08 15.15 19.61 10.27 9.93 8.94 8.65 8.56 13.39 18.96 9.98 8.00 6.31 4.82 4.59 6.46 4.396
P/B Ratio 2.49 2.42 1.43 1.55 2.29 2.11 2.65 2.52 2.48 4.01 4.96 6.32 4.76 11.28 9.88 4.23 4.00 3.32 2.73 4.04 2.738
P/FCF 32.48 29.79 18.42 -13.61 -14.18 -8.42 -9.78 -7.23 -7.57 -7.34 -5.28 -3.65 -4.76 -6.43 -6.55 -10.67 -21.96 -210.88 46.80 26.96 26.961
P/OCF 32.13 29.50 18.19 — — — — — — — — — — — — — — — 43.97 26.34 26.335
EV/EBITDA -23.51 -25.03 356.79 -2.84 -4.38 -2.29 -2.07 -3.28 -3.42 -5.25 -5.30 -3.72 -4.10 -5.74 -6.71 9.77 5.88 3.90 3.32 9.03 9.027
EV/Revenue 6.99 6.88 3.59 8.87 14.33 9.02 11.21 5.90 7.64 8.08 8.35 8.99 12.20 18.57 9.96 5.74 4.68 3.62 3.82 4.85 4.847
EV/EBIT -22.81 -24.23 -1413.45 -2.81 -4.29 -2.24 -2.03 -3.19 -3.38 -5.12 -5.02 -3.48 -3.81 -5.30 -6.06 11.91 6.39 4.07 3.39 9.21 9.214
EV/FCF 19.65 19.07 7.80 -7.71 -10.12 -5.02 -5.59 -4.15 -5.83 -6.63 -5.09 -3.83 -4.34 -6.29 -6.54 -7.65 -16.31 -158.35 38.92 20.21 20.215
Earnings Yield -3.3% -2.8% -0.1% -19.8% -16.4% -26.2% -27.9% -18.2% -21.0% -16.6% -18.5% -30.2% -25.6% -23.6% -22.7% 0.5% 6.6% 16.2% 22.1% 6.6% 6.62%
FCF Yield 3.1% 3.4% 5.4% -7.3% -7.1% -11.9% -10.2% -13.8% -13.2% -13.6% -19.0% -27.4% -21.0% -15.6% -15.3% -9.4% -4.6% -0.5% 2.1% 3.7% 3.71%
PEG Ratio snapshot only 0.006
Price/Tangible Book snapshot only 4.246
EV/OCF snapshot only 19.746
EV/Gross Profit snapshot only 5.104
Acquirers Multiple snapshot only 16.881
Shareholder Yield snapshot only 0.00%
Graham Number snapshot only $8.71
Leverage & Solvency
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Current Ratio 36.41 27.20 35.92 12.21 10.10 7.72 6.68 5.67 6.31 1.18 2.10 2.00 2.88 2.53 3.02 7.85 8.62 5.68 4.89 5.17 5.167
Quick Ratio 36.41 27.20 35.92 12.21 10.10 7.72 6.68 5.67 6.31 0.85 2.10 2.00 2.88 2.47 2.93 7.81 8.57 5.63 4.84 5.12 5.117
Debt/Equity 0.01 0.01 0.01 0.14 0.15 0.25 0.20 0.20 0.66 0.71 0.91 1.83 0.86 1.52 1.51 0.53 0.47 0.41 0.01 0.01 0.007
Net Debt/Equity -0.99 -0.87 -0.82 -0.67 -0.66 -0.85 -1.14 -1.07 -0.57 -0.39 -0.17 0.31 -0.42 -0.23 -0.02 -1.20 -1.03 -0.83 -0.46 -1.01 -1.011
Debt/Assets 0.01 0.01 0.01 0.12 0.12 0.16 0.13 0.13 0.32 0.25 0.29 0.41 0.31 0.34 0.36 0.24 0.23 0.22 0.00 0.00 0.005
Debt/EBITDA -0.20 -0.20 7.33 -0.47 -0.41 -0.46 -0.27 -0.46 -1.19 -1.02 -1.00 -1.03 -0.81 -0.79 -1.03 1.71 0.93 0.64 0.01 0.02 0.020
Net Debt/EBITDA 15.35 14.05 -485.77 2.18 1.76 1.55 1.55 2.43 1.03 0.56 0.19 -0.18 0.40 0.12 0.01 -3.85 -2.04 -1.29 -0.67 -3.01 -3.012
Interest Coverage -4.38 -21.13 -1.27 -596.17 -210.43 -125.81 -104.34 -46.29 -41.67 -29.15 -22.68 -15.60 -13.41 -11.26 -7.78 3.52 7.52 11.87 17.84 12.54 12.535
Equity Multiplier 1.04 1.05 1.03 1.25 1.27 1.54 1.49 1.54 2.06 2.79 3.10 4.45 2.75 4.49 4.21 2.19 2.03 1.84 1.35 1.39 1.391
Cash Ratio snapshot only 4.556
Debt Service Coverage snapshot only 12.795
Cash to Debt snapshot only 148.108
FCF to Debt snapshot only 21.807
Defensive Interval snapshot only 987.7 days
Efficiency & Turnover
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Asset Turnover 0.38 0.40 0.19 0.07 0.08 0.08 0.08 0.15 0.13 0.19 0.22 0.19 0.15 0.13 0.25 0.31 0.37 0.46 0.54 0.49 0.487
Inventory Turnover — — — — — — — — — 0.31 — — — 0.81 6.71 31.40 24.35 9.05 7.28 3.86 3.859
Receivables Turnover 14.88 14.83 2.80 4.17 2.61 2.43 1.74 2.00 2.04 2.38 3.47 2.09 2.80 1.80 5.35 6.62 7.09 6.48 8.45 8.43 8.428
Payables Turnover 1.92 2.44 0.83 0.07 0.08 0.17 0.07 0.15 0.51 0.42 1.36 1.86 — 0.78 — — 3.01 2.16 3.03 0.98 0.983
DSO 25 25 130 88 140 150 210 183 179 153 105 175 130 203 68 55 52 56 43 43 43.3 days
DIO 0 0 0 0 0 0 0 0 0 1178 0 0 0 453 54 12 15 40 50 95 94.6 days
DPO 190 150 442 5568 4484 2196 5031 2371 717 861 268 196 0 470 0 0 121 169 120 371 371.3 days
Cash Conversion Cycle -166 -125 -311 -5480 -4345 -2046 -4820 -2189 -538 470 -163 -22 130 186 123 67 -55 -72 -27 -233 -233.4 days
Fixed Asset Turnover snapshot only 58.956
Operating Cycle snapshot only 137.9 days
Cash Velocity snapshot only 0.614
Capital Intensity snapshot only 2.225
Growth (YoY)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue 1.3% 1.2% -12.1% -65.4% -62.3% -63.5% -52.8% 71.6% 57.3% 1.7% 1.9% 42.4% 47.0% -14.9% 44.9% 1.6% 2.4% 3.5% 2.0% 1.2% 1.19%
Net Income 23.2% 33.0% 99.3% -1.5% -2.3% -3.9% -429.0% -3.5% 0.1% 0.6% 15.5% -97.5% -1.4% -1.6% -1.1% 1.0% 1.4% 1.8% 2.4% 21.0% 21.04%
EPS 90.3% 91.4% 99.6% -1.2% -2.4% -4.0% -429.5% -5.2% 0.8% 9.5% 30.3% -59.8% -75.3% -80.4% -58.9% 1.0% 1.4% 1.7% 2.2% 19.2% 19.24%
FCF 3.5% 6.2% 4.7% -2.0% -2.5% -2.8% -3.1% -1.1% -45.6% -79.9% -1.4% -1.4% -2.2% -1.1% -34.6% 17.4% 65.2% 96.5% 1.2% 1.7% 1.70%
EBITDA -34.9% -47.5% 1.0% -2.8% -3.1% -4.2% -255.7% 1.1% -7.3% -3.8% 16.0% -91.1% -96.1% -78.7% -36.8% 1.6% 1.9% 2.3% 3.3% 1.0% 1.00%
Op. Income 2.1% 2.4% -1.2% -4.8% -5.9% -6.5% -48.1% -10.3% -21.1% -15.6% -6.2% -1.1% -97.4% -77.1% -26.6% -60.3% -1.6% 27.7% 32.2% 1.3% 1.33%
OCF Growth snapshot only 1.72%
Asset Growth snapshot only 18.12%
Equity Growth snapshot only 85.66%
Debt Growth snapshot only -97.60%
Shares Change snapshot only 8.90%
Growth (CAGR)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue 3Y — — — — -2.2% -6.6% -13.5% -8.3% 11.1% 27.8% 6.3% -5.5% -4.5% -6.2% 25.6% 84.9% 98.9% 1.2% 1.3% 1.0% 1.01%
Revenue 5Y — — — — — — — — — — — — 16.7% 13.0% 22.1% 23.2% 47.0% 51.6% 39.3% 36.8% 36.81%
EPS 3Y — — — — — — — — — — — — — — — — — — — — —
EPS 5Y — — — — — — — — — — — — — — — — — — — — —
Net Income 3Y — — — — — — — — — — — — — — — — — — — — —
Net Income 5Y — — — — — — — — — — — — — — — — — — — — —
EBITDA 3Y — — — — — — — — — — — — — — — — — — — — —
EBITDA 5Y — — — — — — — — — — — — — — — — — — — — —
Gross Profit 3Y — — — — -0.0% 0.7% -6.6% -3.6% 20.3% 26.1% -0.8% -18.6% -21.4% -21.0% 18.1% 66.4% 86.4% 1.1% 1.2% 1.0% 1.02%
Gross Profit 5Y — — — — — — — — — — — — 4.2% 5.8% 23.1% 20.5% 49.6% 49.6% 37.0% 37.4% 37.39%
Op. Income 3Y — — — — — — — — — — — — — — — — — — — — —
Op. Income 5Y — — — — — — — — — — — — — — — — — — — 36.1% 36.10%
FCF 3Y — — — — — — — — — — — — — — — — — — — — —
FCF 5Y — — — — — — — — — — — — — — — — — — — 22.6% 22.56%
OCF 3Y — — — — — — — — — — — — — — — — — — — — —
OCF 5Y — — — — — — — — — — — — — — — — — — — 22.9% 22.91%
Assets 3Y 94.2% 70.7% 85.0% 1.1% 1.1% 1.2% 1.3% 1.0% 1.3% 1.5% 18.7% 1.3% 11.8% 10.2% 11.2% 27.3% 31.2% 35.2% 37.7% 42.1% 42.09%
Assets 5Y 7.7% 9.4% 10.7% 12.5% 15.0% 17.1% 20.1% 25.4% 49.3% 45.2% 50.1% 61.8% 71.6% 76.1% 81.0% 83.5% 89.0% 91.0% 25.2% 16.9% 16.88%
Equity 3Y — — — — — — — — — — -16.6% -37.1% -19.1% -32.2% -30.4% 5.7% 12.4% 27.2% 42.3% 47.0% 47.01%
Book Value 3Y — — — — — — — — — — -35.7% -44.3% -26.9% -41.0% -40.1% -10.3% -4.3% 7.5% 18.2% 20.6% 20.65%
Dividend 3Y — — — — — — — — — — — — — — — — — — — — —
Growth Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue Stability 0.78 0.80 0.79 0.37 0.42 0.40 0.29 0.19 0.33 0.54 0.45 0.36 0.13 0.19 0.51 0.40 0.54 0.53 0.53 0.57 0.566
Earnings Stability 0.15 0.21 0.56 0.41 0.26 0.18 0.10 0.21 0.09 0.01 0.06 0.26 0.61 0.62 0.67 0.05 0.00 0.03 0.10 0.30 0.300
Margin Stability 0.88 0.90 0.88 0.90 0.88 0.90 0.90 0.92 0.88 0.95 0.89 0.79 0.78 0.80 0.88 0.80 0.77 0.81 0.90 0.80 0.805
Rev. Growth Consistency 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 0.00 1.00 1.00 1.00 0.50 1.00 1.00 1.000
Earn. Growth Consistency 1.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.000
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Earnings Persistence 0.91 0.87 0.50 0.50 0.50 0.50 0.50 0.99 1.00 1.00 0.94 0.50 0.50 0.50 0.50 0.20 0.20 0.20 0.20 0.50 0.500
Earnings Smoothness — — — — — — — — — — — — — — — — — — — 0.00 0.000
ROE Trend — — — — — — -0.64 -0.26 -0.29 -0.36 -0.55 -1.53 -0.77 -2.05 -1.41 1.21 1.13 2.20 2.18 1.21 1.212
Gross Margin Trend 0.11 0.09 0.10 0.12 0.14 0.05 0.01 -0.02 -0.02 -0.08 -0.20 -0.37 -0.44 -0.36 -0.07 -0.04 0.08 0.13 0.08 0.29 0.293
FCF Margin Trend 2.07 1.36 1.01 -1.24 -1.43 -1.90 -2.18 -1.05 -0.78 -0.50 -0.87 -1.06 -1.45 -1.44 0.30 1.13 1.77 2.06 1.68 1.79 1.789
Sustainable Growth Rate — — — — — — — — — — — — — — — 3.5% 34.8% 85.7% 1.0% 34.8% 34.80%
Internal Growth Rate — — — — — — — — — — — — — — — 1.3% 18.1% 56.2% 1.2% 26.3% 26.34%
Cash Flow Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
OCF/Net Income -0.96 -1.22 -77.56 0.37 0.43 0.45 0.36 0.76 0.62 0.81 1.02 0.90 0.82 0.66 0.67 -17.48 -0.66 -0.02 0.10 0.57 0.573
FCF/OCF 0.99 0.99 0.99 1.00 1.01 1.00 1.01 1.00 1.01 1.01 1.01 1.00 1.00 1.00 1.00 1.01 1.04 1.52 0.94 0.98 0.977
FCF/Net Income snapshot only 0.560
OCF/EBITDA snapshot only 0.457
CapEx/Revenue 0.4% 0.4% 0.6% 0.5% 0.7% 0.9% 1.1% 0.7% 1.5% 1.1% 1.0% 1.0% 0.3% 0.0% 0.2% 0.5% 1.0% 0.8% 0.6% 0.6% 0.57%
CapEx/Depreciation snapshot only 0.522
Accruals Ratio -0.28 -0.26 -0.09 -0.15 -0.16 -0.18 -0.29 -0.07 -0.10 -0.05 0.01 -0.05 -0.09 -0.20 -0.19 0.24 0.25 0.37 0.49 0.09 0.089
Sloan Accruals snapshot only 0.013
Cash Flow Adequacy snapshot only 43.095
Earnings Quality Score snapshot only 0.500
Dividends & Buybacks
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio — — — — — — — — — — — — — — — 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
FCF Payout Ratio 0.0% 0.0% 0.0% — — — — — — — — — — — — — — — 0.0% 0.0% 0.00%
Total Payout Ratio — — — — — — — — — — — — — — — 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Div. Increase Streak — — — — — — — — — — — — — — — — — — — — —
Chowder Number — — — — — — — — — — — — — — — — — — — — —
Buyback Yield 0.0% 0.9% 4.3% 4.9% 3.5% 3.0% 1.8% 2.0% 2.1% 1.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield -16.5% -16.7% 1.5% 4.3% 3.5% 2.8% 1.6% 1.8% 1.8% -1.2% -3.1% -3.6% -21.7% 0.0% -0.2% -0.4% -10.5% -2.4% -3.6% -2.2% -2.21%
Total Shareholder Return -16.5% -16.7% 1.5% 4.3% 3.5% 2.8% 1.6% 1.8% 1.8% -1.2% -3.1% -3.6% -21.7% 0.0% -0.2% -0.4% -10.5% -2.4% -3.6% -2.2% -2.21%
DuPont Factors
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Tax Burden (NI/EBT) 1.00 1.00 1.32 0.98 0.98 0.98 0.98 0.99 1.00 1.00 1.00 1.00 1.00 1.17 1.22 0.12 0.66 0.96 0.93 0.84 0.841
Interest Burden (EBT/EBIT) 1.23 1.05 1.79 1.00 1.00 1.00 1.01 1.02 0.92 0.94 0.96 1.00 1.07 1.09 1.13 0.72 0.87 0.92 0.97 0.97 0.968
EBIT Margin -0.31 -0.28 -0.00 -3.16 -3.34 -4.03 -5.52 -1.85 -2.26 -1.58 -1.66 -2.58 -3.20 -3.51 -1.65 0.48 0.73 0.89 1.13 0.53 0.526
Asset Turnover 0.38 0.40 0.19 0.07 0.08 0.08 0.08 0.15 0.13 0.19 0.22 0.19 0.15 0.13 0.25 0.31 0.37 0.46 0.54 0.49 0.487
Equity Multiplier 2.14 2.37 1.05 1.14 1.14 1.23 1.20 1.37 1.60 2.10 2.15 2.48 2.41 3.45 3.61 2.68 2.27 2.38 1.83 1.67 1.669
Per Share
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
EPS (Diluted TTM) $-0.30 $-0.24 $-0.00 $-0.88 $-1.02 $-1.20 $-1.53 $-0.93 $-1.01 $-1.09 $-1.07 $-1.48 $-1.78 $-1.97 $-1.70 $0.05 $0.63 $1.45 $2.06 $0.95 $0.95
Book Value/Share $3.74 $3.60 $3.52 $2.88 $2.72 $2.18 $2.07 $2.02 $1.94 $1.63 $1.17 $0.78 $1.46 $0.74 $0.76 $2.08 $2.38 $2.70 $3.42 $3.55 $3.68
Tangible Book/Share $3.74 $3.60 $3.52 $2.88 $2.72 $2.18 $2.07 $2.02 $1.94 $-0.32 $-0.56 $-0.92 $-0.12 $-0.63 $-0.57 $1.87 $2.18 $2.51 $3.24 $3.38 $3.38
Revenue/Share $0.81 $0.81 $0.59 $0.28 $0.31 $0.30 $0.28 $0.50 $0.49 $0.73 $0.67 $0.57 $0.52 $0.44 $0.75 $1.10 $1.51 $1.86 $2.03 $2.22 $2.30
FCF/Share $0.29 $0.29 $0.27 $-0.33 $-0.44 $-0.55 $-0.56 $-0.71 $-0.64 $-0.89 $-1.10 $-1.34 $-1.46 $-1.30 $-1.14 $-0.83 $-0.43 $-0.04 $0.20 $0.53 $0.55
OCF/Share $0.29 $0.30 $0.28 $-0.33 $-0.44 $-0.54 $-0.56 $-0.70 $-0.63 $-0.88 $-1.09 $-1.34 $-1.46 $-1.30 $-1.14 $-0.82 $-0.42 $-0.03 $0.21 $0.54 $0.56
Cash/Share $3.73 $3.18 $2.94 $2.35 $2.20 $2.40 $2.76 $2.58 $2.40 $1.79 $1.26 $1.18 $1.87 $1.29 $1.16 $3.60 $3.57 $3.34 $1.59 $3.61 $3.75
EBITDA/Share $-0.24 $-0.22 $0.01 $-0.89 $-1.02 $-1.19 $-1.52 $-0.89 $-1.08 $-1.13 $-1.06 $-1.38 $-1.54 $-1.42 $-1.11 $0.65 $1.20 $1.72 $2.33 $1.19 $1.19
Debt/Share $0.05 $0.05 $0.04 $0.42 $0.41 $0.54 $0.41 $0.41 $1.29 $1.15 $1.06 $1.42 $1.25 $1.12 $1.14 $1.11 $1.12 $1.10 $0.02 $0.02 $0.02
Net Debt/Share $-3.69 $-3.13 $-2.90 $-1.93 $-1.79 $-1.86 $-2.35 $-2.17 $-1.11 $-0.63 $-0.20 $0.24 $-0.62 $-0.17 $-0.01 $-2.49 $-2.44 $-2.23 $-1.57 $-3.59 $-3.59
Academic Models
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Altman Z-Score — — — — — — — — — — — — — — — — — — — — 6.501
Altman Z-Prime snapshot only 12.796
Piotroski F-Score 5 5 6 2 2 2 2 3 3 3 2 2 3 3 4 6 6 6 7 6 6
Beneish M-Score -3.57 -2.33 7.50 40.90 32.61 1.11 -3.17 1.58 -2.89 1.90 44.21 38.65 39.58 -3.87 0.05 1.72 2.96 0.29 -0.01 -1.71 -1.711
Ohlson O-Score snapshot only -10.167
ROIC (Greenblatt) snapshot only 34.92%
Net-Net WC snapshot only $2.71
Credit
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Credit Rating snapshot only AA+
Credit Score 70.07 71.33 60.43 37.54 42.74 31.80 33.17 31.71 30.23 21.02 28.80 23.46 29.50 26.17 26.48 53.53 70.46 78.17 95.71 94.66 94.661
Credit Grade snapshot only 2
Credit Trend snapshot only 41.130
Implied Spread (bps) snapshot only 65.000
Industry Credit Rank snapshot only 94
Sector Credit Rank snapshot only 90

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms